The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Antibiotic Resistance and New Antimicrobial drugs
Volume 14 - 2024 |
doi: 10.3389/fcimb.2024.1499325
Synergistic Efficacy of Phage Henu10 with Antibiotics against Shigella dysenteriae with insight into Phage Resistance and Fitness Trade-Offs
Provisionally accepted
Baohong Chen
1*
Jing Zhao
1*
Weizhen Wang
1*
Yu Kang
1*
Erli Hu
1*
Yuan Zhang
1*
Huiling Chen
1*
Xiao Xu
2*
Xin-Ying Ji
2
Yuhan Wang
2*
Tieshan Teng
2*
Salwa Gomaa
3*- 1 Hua Country People's Hospital, Anyang, China
- 2 Henan University, Kaifeng, China
- 3 Zagazig University, Zagazig, Al Sharqia, Egypt
The irrational use of antibiotics has facilitated the emergence of multidrug-resistant Shigella spp., undermining the effectiveness of the currently available antibiotics. Consequently, there is an urgent need to explore new approaches, with phage therapy emerging as a promising alternative. In this study, we isolated a phage targeting Shigella dysenteriae from sewage samples, designated Henu10.The morphology, biological characteristics, genomic composition, and phylogenetic relationships of Henu10 were thoroughly characterized. To investigate the trade-off relationship between phage resistance and bacterial fitness, phage Henu10-resistant strains R6 and R11 were identified using continuous passage and bidirectional validation methods. Phage-resistant strains R6 and R11 exhibited impaired adsorption, increased sensitivity to temperature and pH stress, heightened susceptibility to certain antibiotics (such as ciprofloxacin and kanamycin), reduced biofilm-forming capacity, and diminished colonization ability in vivo compared to the wild-type strain. These results indicate that phage Henu10 may effectively control the pathogenic bacteria associated with S. dysenteriae, representing a promising new therapeutic option for treating S. dysenteriae infections.
Keywords: Shigella dysenteriae1, Shigellosis2, antibiotic resistance3, phage therapy4, phage-resistance5, phage-antibiotics synergy6, fitness cost7
Received: 20 Sep 2024; Accepted: 18 Nov 2024.
Copyright: © 2024 Chen, Zhao, Wang, Kang, Hu, Zhang, Chen, Xu, Ji, Wang, Teng and Gomaa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Baohong Chen, Hua Country People's Hospital, Anyang, China
Jing Zhao, Hua Country People's Hospital, Anyang, China
Weizhen Wang, Hua Country People's Hospital, Anyang, China
Yu Kang, Hua Country People's Hospital, Anyang, China
Erli Hu, Hua Country People's Hospital, Anyang, China
Yuan Zhang, Hua Country People's Hospital, Anyang, China
Huiling Chen, Hua Country People's Hospital, Anyang, China
Xiao Xu, Henan University, Kaifeng, China
Yuhan Wang, Henan University, Kaifeng, China
Tieshan Teng, Henan University, Kaifeng, China
Salwa Gomaa, Zagazig University, Zagazig, 44519, Al Sharqia, Egypt
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.